Aim: This study aims to identify the prognostic and diagnostic significance of protein kinase-coding genes in pancreatic ductal adenocarcinoma (PDAC), products of which constitute one of the main classes of drug targets in cancer treatment. Material and Methods: Whole-genome gene expression data from seven PDAC cohorts (GSE62452, GSE15471, GSE62165, GSE18670, GSE19280, GSE41368, GSE71989) were included in the integrative transcriptomic analysis (n tumor=252, ncontrol=131). The differentially expressed genes in PDAC compared to controls were identified using random- effects model and were further validated in TCGA (The Cancer Genome Atlas) combined GTEx (Genotype-Tissue Expression) cohort (n tumor=179, ncontrol=171). The prognostic significance of the identified genes was then evaluated by integrating survival and transcriptome data of over 530 (n=530-1302) patients using OSpaad. Results: The integrative transcriptomic analysis revealed a total of seven down-regulated and 33 up-regulated protein kinase-coding genes in PDAC (adjusted p-value <= 0,05, -2 <= z-value <= 2). The validation analysis using TCGA combined GTEx data confirmed 80% (n=32) of the identified differentially expressed genes in PDAC (p<0,01, and fold change >= 2). Amongst, the elevated mRNA expressions of 9 genes (PTK2, TAOK1, CSNK1A1, EIF2AK2, WNK1, CDK12, CDK6, GSK3B, and MAP4K4) were found to be significantly correlated with worse overall survival of patients with PDAC (Logrank p <= 0,05, HR>1). Overexpression of SYK and PRKACB were correlated with better overall survival (Logrank p <= 0,05, HR<1). Discussion: The results of this study suggest that mRNA expression of the identified eleven protein kinase-coding genes can be used as both prognostic and diagnostic biomarkers for further clinical validation.